These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23186990)

  • 1. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2013; 34(1):1-114. PubMed ID: 23186990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2014; 42(4):1079-149. PubMed ID: 25061058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 41(4):961-1019. PubMed ID: 24898652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
    Gualtieri F; Manetti D; Romanelli MN; Ghelardini C
    Curr Pharm Des; 2002; 8(2):125-38. PubMed ID: 11812254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J
    Neuropharmacology; 2013 Jan; 64():124-36. PubMed ID: 22771768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AMPA receptor potentiators as cognitive enhancers.
    O'Neill MJ; Dix S
    IDrugs; 2007 Mar; 10(3):185-92. PubMed ID: 17351873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment strategies for the cognitive deficits of Alzheimer's disease.
    Meador KJ
    J S C Med Assoc; 1994 Nov; 90(11):543-7. PubMed ID: 7853858
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards better brain management: nootropics.
    Malik R; Sangwan A; Saihgal R; Jindal DP; Piplani P
    Curr Med Chem; 2007; 14(2):123-31. PubMed ID: 17266573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of mild cognitive impairment: value of citicoline].
    Abad-Santos F; Novalbos-Reina J; Gallego-Sandín S; García AG
    Rev Neurol; 2002 Oct 1-15; 35(7):675-82. PubMed ID: 12389156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging cognitive enhancing drugs.
    Buccafusco JJ
    Expert Opin Emerg Drugs; 2009 Dec; 14(4):577-89. PubMed ID: 19772371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Trends in the Animal Models for Screening of Nootropic Agents: A Systematic Review.
    Grover S; Jain S
    Curr Rev Clin Exp Pharmacol; 2023; 18(3):255-269. PubMed ID: 35469584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs.
    Malík M; Tlustoš P
    Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual inhibitor of PDE7 and GSK-3-VP1.15 acts as antipsychotic and cognitive enhancer in C57BL/6J mice.
    Lipina TV; Palomo V; Gil C; Martinez A; Roder JC
    Neuropharmacology; 2013 Jan; 64():205-14. PubMed ID: 22749842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.